



PHARMAGEST
WELCOOP SOLUTION

PRESS RELEASE
For immediate release

**RESULTS OF THE VOTE OF THE RESOLUTIONS
SUBMITTED TO THE ANNUAL GENERAL MEETING
HELD ON JUNE 21, 2013**

Number of shares making up the share capital : 3.034.825

Number of voting shares owned by shareholders present or represented or having voted by mail : 2.369.967

The Annual Ordinary General Meeting was held on June 21, 2013 and approved the financial statements and the consolidated financial statements for the fiscal year ended December 31, 2012. Hereafter the result of the votes of the resolutions submitted by the company's Board of Directors:

Resolutions	Result of votes
<ul style="list-style-type: none"> ▪ FIRST RESOLUTION Approval of the company's financial statements 	Resolution adopted unanimously.
<ul style="list-style-type: none"> ▪ SECOND RESOLUTION Discharge to directors 	Resolution adopted by: - 2.353.512 votes in favor, - 16.455 votes against.
<ul style="list-style-type: none"> ▪ THIRD RESOLUTION Approval of the consolidated financial statements 	Resolution adopted unanimously.
<ul style="list-style-type: none"> ▪ FORTH RESOLUTION Allocation of the result 	Resolution adopted by: - 2.209.616 votes in favor, - 160.351 votes against.
<ul style="list-style-type: none"> ▪ FIFTH RESOLUTION Regulated agreements 	Resolution adopted by: - 2.369.522 votes in favor, - 445 votes against.
<ul style="list-style-type: none"> ▪ SIXTH RESOLUTION Authorization for the company to buy back its own shares 	Resolution adopted by: - 2.209.837 votes in favor, - 160.130 votes against.
<ul style="list-style-type: none"> ▪ SEVENTH RESOLUTION Attendance fees 	Resolution adopted by: - 2.369.522 votes in favor, - 445 votes against.
<ul style="list-style-type: none"> ▪ EIGHTH RESOLUTION Ratification of the appointment of Mr Denis SUPPLISSON as a director 	Resolution adopted by: - 2.299.173 votes in favor, - 70.794 votes against.
<ul style="list-style-type: none"> ▪ NINTH RESOLUTION Powers for formalities 	Resolution adopted unanimously.

DIVIDENDS

PHARMAGEST INTERACTIVE, at its Annual Ordinary General Meeting of June 21, 2013, decided the payment of a dividend amounting to 2.10 Euros per share. The dividend will be payable on **June 28, 2013** (instead of September 2, 2013). The ex-dividend date will be June 25, 2013.

About the PHARMAGEST Group:

The PHARMAGEST Group is the French leader in computer systems for pharmacies, with a 43.5 % share of the market, 9,800 clients and more than 700 employees. Since September 2007, the PHARMAGEST Group has also been present in Northern Europe with a 12 % market share in Belgium and Luxembourg through its subsidiary SABCO.

As a privileged partner to pharmacists for almost 30 years now, the PHARMAGEST Group designs innovative computer solutions for pharmacies and is developing a high potential E-Business E-Media activity intended for laboratories.

The PHARMAGEST Group is also developing previously unpublished software solutions for Retirement Homes, (Care Homes and day centres for the elderly), through its subsidiary MALTA INFORMATIQUE.

The first Logiciel de Gestion à Portail Intégré (Integrated Portal Management Software - LGPI Global Services®), creator of value for the patient, pharmacist and laboratory, dynamises sales, optimises purchases and enriches advice to the patient. It is also the first permanent impact medium for pharmacies, supplying laboratories with direct communication towards the pharmacist and his patients.

At the heart of the digital revolution that is gradually establishing itself in the daily life of health professionals and patients alike, at the beginning of 2012, the PHARMAGEST Group created an e-Health business, bringing together the subsidiaries DIATELIC (telemedicine and e-health solutions) and DOMEDIC EUROPE (intelligent pill dispenser DO-Pill Secure™).

Listed on the NYSE Euronext Paris™ - Compartment B

Eligible for the Long-Only Deferred Settlement Service (SRD)

Indices CAC ® SMALL90 and CAC ® All-Tradable by inclusion
ISIN: FR 0000077687 – Reuters: PHA.PA – Bloomberg: - PMGI FP



Find out the latest news from the group at www.pharmagest.com

Contacts :

Analysts and Investor Relations:

Administrative and Financial Director: Jean-Yves SAMSON
Tel. 03 83 15 90 67 – jean-yves.samson@pharmagest.com

Press Relations:

FIN'EXTENSO – Isabelle APRILE
Tel. 01 39 97 61 22 - i.aprile@finextenso.fr